A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer

Trial ID # NCT00003998; SCOTROC
Phase III
Drug Class Chemotherapy
Drug Name Docetaxel
Alternate Drug Names Taxotere
Drugs in Trial Carboplatin, Docetaxel, Paclitaxel
Eligible Participant

Newly diagnosed stage IC-IV ovarian cancer

Patients Enrolled


Therapy Setting


Study Design



ORR, PFS, OS, evaluated per RECIST


CarboPt+Pac (n=538) vs CarboPt+Doc (n=539):

ORR: 59.5 vs 58.7%
PFS: 14.8 vs 15.0 months, HR: 0.97 (0.83-1.13, p=0.707)
2-year survival rates: 68.9 vs 64.2%,  HR: 1.13 (0.92-1.39, p=0.238)

Clinically Significant Adverse Events

CarboPt+Pac vs CarboPt+Doc:
Serious AE:
Grade 3-4 AE: neutropenia (84 vs 94%)
Grade 2-4 AE: neurosensory toxicity (30 vs 11%), neuromotor toxicity (7 vs 3%)


Carboplatin+docetaxel is similar to carboplatin+paclitaxel in terms of response rates and PFS and OS


Vasey PA et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2014) 96(22):1682-91

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.